Editas Medication Declares Third Quarter 2022 Outcomes and

Editas Medication Declares Third Quarter 2022 Outcomes and

Dosed second affected person with EDIT-301 within the Part 1/2 RUBY trial for sickle cell illness

On monitor to announce preliminary preliminary scientific knowledge from RUBY trial by year-end

Accomplished cell enhancing and presently scheduling first affected person dosing with EDIT-301 in Part 1/2 EDITHAL trial for TDT

Firm to supply a scientific replace on the Part 1/2 BRILLIANCE trial for EDIT-101 this month

CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) — Editas Medication, Inc. (Nasdaq: EDIT), a scientific stage genome enhancing firm, at present reported enterprise highlights and monetary outcomes for the third quarter of 2022.

“I’m happy with our continued progress, and I look ahead to offering scientific updates on EDIT-101 and EDIT-301 within the subsequent two months,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Govt Officer, Editas Medication. “We’re targeted on positioning and advancing our portfolio in the direction of our objective of bringing differentiated medicines to individuals dwelling with critical illnesses.”

Current Achievements and Outlook

Ex Vivo Medicines

  • EDIT-301 for Sickle Cell Illness
    Second affected person dosed in RUBY trial; on monitor to supply preliminary scientific knowledge by year-end
    • Editas Medication has dosed the second affected person and continues to enroll examine individuals within the Part 1/2 RUBY trial for the therapy of extreme sickle cell illness.
    • The Firm stays on monitor to current preliminary preliminary scientific knowledge for the RUBY examine by year-end.
  • EDIT-301 for Transfusion-Dependent Beta Thalassemia (TDT)
    First affected person apheresis and enhancing accomplished
    • The Firm has accomplished enhancing CD34+ hematopoietic stem cells for the primary enrolled affected person within the Part 1/2 EDITHAL trial for TDT and is scheduling dosing.

In Vivo Medicines 

  • EDIT-101 for Leber Congenital Amaurosis 10 (LCA10)
    BRILLIANCE scientific replace to be supplied this month
    • The Firm stays on monitor to supply an replace on the Part 1/2 BRILLIANCE scientific trial this month, together with security and efficacy knowledge.
  • EDIT-103 for Rhodopsin-Related Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
    Introduced preclinical knowledge at ESGCT
    • In October, Editas Medication offered preclinical knowledge throughout an oral presentation on the European Society of Gene and Cell Remedy (ESGCT) Annual Assembly.
    • The information demonstrated almost 100% gene enhancing knockout of the endogenous RHO gene, with the substitute RHO gene producing over 30% of regular RHO protein ranges within the handled space of subretinal injection in non-human primates handled with EDIT-103.

Mobile Therapies

  • EDIT-202 Multiplexed iNK for Stable Tumors
    Introduced new preclinical knowledge at ESGCT
    • In October, the Firm offered new preclinical knowledge in a poster presentation on the ESGCT Annual Assembly. EDIT-202 is an engineered iNK cell product, presently in preclinical improvement, that mixes Editas Medication’s proprietary AsCas12a enzyme and SLEEK™ gene enhancing expertise, and seeks to deal with the unmet want for treating strong tumors.
    • The information demonstrated extended persistence, excessive cytotoxicity, and enhanced in vivo management of strong tumors.

Third Quarter 2022 Monetary Outcomes

  • Money, money equivalents, and marketable securities as of September 30, 2022, had been $478.5 million, in comparison with $527.6 million as of June 30, 2022. The Firm expects that its current money, money equivalents and marketable securities will allow it to fund its working bills and capital expenditures into 2024.
  • For the three months ended September 30, 2022, internet loss attributable to frequent stockholders was $55.7 million, or $0.81 per share, in comparison with internet lack of $39.1 million, or $0.57 per share, for a similar interval in 2021.
  • Collaboration and different analysis and improvement revenues had been $42 thousand for the three months ended September 30, 2022, in comparison with $6.2 million for a similar interval in 2021. The 2021 interval included income acknowledged for an opt-in by Bristol Myers Squibb (BMS) beneath the Firm’s collaboration with BMS; there was no corresponding income within the third quarter of 2022.
  • Analysis and improvement bills had been $41.3 million for the three months ended September 30, 2022, in comparison with $29.3 million for a similar interval in 2021. The rise was primarily pushed by elevated manufacturing bills, in addition to scientific trial prices.
  • Basic and administrative bills had been flat at $16.2 million for the three months ended September 30, 2022, in comparison with the identical interval in 2021.

Editas Medication plans to take part within the following scientific and medical conferences:

  • Society for Immunotherapy of Most cancers (SITC) 37th Annual Assembly
    November 8-12, 2022 – Boston, MA
  • American Society for Hematology (ASH) 64th Annual Assembly
    December 10-13, 2022 – New Orleans, LA

Editas Medication plans to take part within the following investor occasions:

  • 5th Annual Evercore ISI HealthCONx Convention
    November 29, 2022 – Digital

Convention Name
The Editas Medication administration group will host a convention name and webcast at present at 8:00 a.m. ET to supply and talk about a company replace and monetary outcomes for the third quarter of 2022. To entry the decision, please dial 877-407-0989 (home) or 201-389-0921 (worldwide) and ask for the Editas Medication earnings name. A dwell webcast of the decision can even be out there on the Buyers part of the Editas Medication web site at www.editasmedicine.com, and a replay will likely be out there roughly two hours after its completion.

About Editas Medication
As a scientific stage genome enhancing firm, Editas Medication is targeted on translating the ability and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome enhancing methods into a sturdy pipeline of remedies for individuals dwelling with critical illnesses all over the world. Editas Medication goals to find, develop, manufacture, and commercialize transformative, sturdy, precision genomic medicines for a broad class of illnesses. Editas Medication is the unique licensee of Broad Institute’s and Harvard College’s Cas9 patent estates and Broad Institute’s Cas12a patent property for human medicines. For the most recent info and scientific shows, please go to www.editasmedicine.com.

Ahead-Wanting Statements
This press launch accommodates forward-looking statements and data inside the which means of The Non-public Securities Litigation Reform Act of 1995. The phrases ‘‘anticipate,’’ ‘‘consider,’’ ‘‘proceed,’’ ‘‘may,’’ ‘‘estimate,’’ ‘‘count on,’’ ‘‘intend,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘mission,’’ ‘‘goal,’’ ‘‘ought to,’’ ‘‘would,’’ and comparable expressions are supposed to establish forward-looking statements, though not all forward-looking statements include these figuring out phrases. Ahead-looking statements on this press launch embody statements concerning the initiation, timing, progress and outcomes of the Firm’s preclinical and scientific research and its analysis and improvement packages, the timing for the Firm’s receipt and presentation of knowledge from its scientific trials and preclinical research, together with preliminary preliminary scientific knowledge from the RUBY trial by year-end 2022 and a scientific replace on the BRILLIANCE trial in November 2022, potential of, and expectations for, the Firm’s product candidates, the timing or chance of regulatory filings and approvals, and the Firm’s expectations concerning money runway. The Firm might not really obtain the plans, intentions, or expectations disclosed in these forward-looking statements, and you shouldn’t place undue reliance on these forward-looking statements. Precise outcomes or occasions may differ materially from the plans, intentions and expectations disclosed in these forward-looking statements on account of varied vital components, together with: uncertainties inherent within the initiation and completion of pre-clinical research and scientific trials, together with the BRILLIANCE, RUBY and EDITHAL trials, and scientific improvement of the Firm’s product candidates; availability and timing of outcomes from pre-clinical research and scientific trials; whether or not interim outcomes from a scientific trial will likely be predictive of the ultimate outcomes of the trial or the outcomes of future trials; expectations for regulatory approvals to conduct trials or to market merchandise and availability of funding enough for the Firm’s foreseeable and unforeseeable working bills and capital expenditure necessities. These and different dangers are described in higher element beneath the caption “Threat Elements” included within the Firm’s most up-to-date Annual Report on Kind 10-Ok, which is on file with the Securities and Alternate Fee, as up to date by the Firm’s subsequent filings with the Securities and Alternate Fee, and in different filings that the Firm might make with the Securities and Alternate Fee sooner or later. Any forward-looking statements contained on this press launch symbolize Firm’s views solely as of the date hereof and shouldn’t be relied upon as representing its views as of any subsequent date. Besides as required by regulation, the Firm explicitly disclaims any obligation to replace any forward-looking statements.

EDITAS MEDICINE, INC.
Consolidated Assertion of Operations
(quantities in 1000’s, besides share and per share knowledge)
(Unaudited)

  Three Months Ended
  9 Months Ended
  September 30,
  September 30,
    2022     2021     2022     2021
                       
Collaboration and different analysis                       
and improvement revenues $ 42   $ 6,197   $ 13,176   $ 13,075
Working bills:                      
Analysis and improvement   41,326     29,265     122,960     104,954
Basic and administrative   16,236     16,185     52,720     59,657
Complete working bills   57,562     45,450     175,680     164,611
Working loss   (57,520)     (39,253)     (162,504)     (151,536)
Different earnings, internet:                      
Different earnings, internet   1     19     4     38
Curiosity earnings, internet   1,793     152     2,806     432
Complete different earnings, internet   1,794     171     2,810     470
Internet loss $ (55,726)   $ (39,082)   $ (159,694)   $ (151,066)
Internet loss per share attributable                      
to frequent stockholders,                      
primary and diluted $ (0.81)   $ (0.57)   $ (2.33)   $ (2.24)
Weighted-average frequent                      
shares excellent, primary and                      
diluted   68,736,125     68,219,742     68,621,574     67,371,246
                       

EDITAS MEDICINE, INC.
Chosen Consolidated Steadiness Sheet Gadgets
(quantities in 1000’s)
(Unaudited)

  September 30,   December 31,
  2022   2021
 
Money, money equivalents, and marketable securities $ 478,461   $ 619,916
Working capital   384,340     460,426
Complete belongings   531,029     677,483
Deferred income, internet of present portion   64,667     60,888
Complete stockholders’ fairness   414,745     553,642

Media Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

Investor Contact:
Ron Moldaver
(617) 401-9052
ir@editasmed.com